Ibogaine vs psilocybin is increasingly the comparison clinicians and patients ask about as both medicines move closer to mainstream psychiatric practice. The short answer: they act on different receptor systems, address different conditions most effectively, and carry different medical risk profiles. Treating them as interchangeable alternatives misses the mechanism differences that make each medicine what it is.
Ibogaine vs psilocybin: ibogaine acts on at least six receptor systems simultaneously — including the opioid and NMDA receptors central to addiction and withdrawal — with a 12–24 hour experience. Psilocybin acts primarily through the 5-HT2A serotonin receptor, disrupting the default mode network, with a 4–6 hour experience. Ibogaine is the only psychedelic compound with a mechanism specific enough to interrupt opioid withdrawal. Psilocybin has more published RCT data for treatment-resistant depression.
How the Receptor Profiles Differ
Psilocybin is metabolised rapidly to psilocin, which binds with high affinity to the 5-HT2A serotonin receptor. That binding decreases activity in the default mode network — the brain's self-referential processing system. The experience typically lasts 4–6 hours. Recent research from Uppsala University suggests psilocin also binds to TrkB receptors for BDNF (brain-derived neurotrophic factor), which may partly explain its antidepressant effects independently of the serotonin pathway.
Ibogaine operates across multiple receptor systems at once: kappa and mu-opioid receptors, NMDA glutamate receptors, the serotonin transporter (SERT), sigma-2 receptors, dopamine receptors, and nicotinic acetylcholine receptors. No other psychedelic compound has this receptor breadth. The opioid receptor activity is why ibogaine can interrupt physical opioid withdrawal — psilocybin has no mechanism for this. The NMDA activity is why ibogaine resets hyperactive craving circuits that persist long after acute withdrawal resolves.
Both compounds increase BDNF and promote neuroplasticity beyond the acute experience. With ibogaine, the active metabolite noribogaine extends this neuroplasticity window for weeks to months. With psilocybin, the window is shorter and less biochemically defined, though consistently observed in clinical settings.
Duration and physical demand differ substantially. Psilocybin: 4–6 hours, physiologically gentle, manageable for most people with adequate preparation. Ibogaine: 12–24 hours, physically demanding, requiring medical oversight throughout because of its effects on the cardiovascular system.
What the Clinical Research Shows
The evidence bases are at different stages of development, and understanding what kind of evidence exists for each changes how to read the comparison.
Psilocybin has two landmark randomised controlled trials for treatment-resistant depression. The COMPASS Pathways Phase 2b trial (2022) enrolled 233 patients and found a single 25mg dose produced significant improvements in depression scores at three weeks. The Imperial College London trial published in The New England Journal of Medicine (2021) found psilocybin comparable to escitalopram for major depressive disorder over six weeks. The FDA granted psilocybin Breakthrough Therapy designation for treatment-resistant depression and MDD. This is a stronger evidence base, by RCT standards, than ibogaine currently has for depression specifically.
Ibogaine's most prominent recent evidence is the 2023 Stanford study published in Nature Medicine, which treated 30 special operations veterans with treatment-resistant PTSD, traumatic brain injury, and depression. At one month: 88% reduction in PTSD symptoms, 87% in depression, 81% in anxiety. The study had no placebo arm and a small sample — genuine methodological limitations that do not diminish the direction of the findings. A 2026 iScience study of the same population found cortical thickening in 11 brain regions and a predicted brain age reduction of 1.3 years at one month. These are the strongest ibogaine depression and PTSD findings in the literature, but they exist in a different methodological category from the psilocybin RCTs.
For opioid dependence specifically, the research landscape reverses. Ibogaine has 30 years of observational data, multiple published case series, and the unique mechanistic claim that it interrupts physical withdrawal through opioid receptor activity. Psilocybin has no clinical evidence for opioid dependence comparable to ibogaine's. Early research shows psilocybin may assist with tobacco cessation and alcohol use disorder — conditions where psychological craving rather than physical receptor dependence is the primary barrier. For opioid dependence specifically, ibogaine is the mechanism-appropriate choice.
Where Ibogaine Has the Stronger Case
Opioid dependence. There is no comparable compound for interrupting physical opioid withdrawal. The combination of kappa-opioid receptor agonism, NMDA reset, and GDNF upregulation in the ventral tegmental area produces a neurological disruption of craving and withdrawal that psilocybin cannot replicate. For someone physically dependent on opioids — fentanyl, heroin, prescription opioids — ibogaine is the mechanism-specific choice.
Polysubstance dependence with comorbid trauma. The Stanford study population — veterans with blast TBI, PTSD, and in many cases substance use history — represents a profile that is difficult to address with any single conventional intervention. Ibogaine's multi-system mechanism appears suited to complex presentations where addiction and trauma are not separable.
Treatment-resistant presentations in people who have already failed multiple prior interventions. The research consistently describes ibogaine's strongest results in this population. The people who come with the most evidence that nothing else has worked tend to be the ones who are genuinely ready for what the medicine shows them, rather than hoping it will do the work for them. That readiness produces better outcomes.
Where Psilocybin Has the Stronger Case
Treatment-resistant depression without a significant addiction component. The randomised controlled trial evidence for psilocybin in this domain is more developed than ibogaine's. For straightforward treatment-resistant MDD not complicated by substance dependence, the evidence base tilts toward psilocybin-assisted therapy as the more thoroughly studied option.
End-of-life existential distress. The Johns Hopkins and NYU studies on psilocybin for cancer-related existential distress are among the most striking findings in the psychedelic research literature — single doses producing lasting reductions in death anxiety and depression. This is a specific clinical application where psilocybin's gentler physiological profile and the character of the experience it produces are well-matched to the need.
People for whom ibogaine's medical contraindications apply. Ibogaine prolongs the QT interval and carries cardiac risk that psilocybin does not. Someone who has QT prolongation, significant cardiac history, or is on medications that cannot be safely tapered may be a better candidate for psilocybin if their condition is one psilocybin addresses.
Medical Screening and Contraindications
Psilocybin's medical risk is primarily psychological rather than physiological. It does not carry cardiac risk. The main contraindications are a personal or family history of psychosis or schizophrenia-spectrum disorder, current lithium (seizure risk), and current MAOIs (interaction risk). For most people without these factors, psilocybin in a supervised context is physiologically safe.
Ibogaine carries a different medical profile. It prolongs the QT interval — the specific cardiac mechanism behind documented fatalities. An EKG is required before every ceremony. QT prolongation (QTc above 450–500ms), significant cardiac arrhythmia, and recent myocardial infarction are absolute contraindications. Current SSRIs or SNRIs are absolute contraindications due to serotonin syndrome risk — a supervised taper under the prescribing physician is required before ceremony is possible. Methadone requires a specific transition protocol. Severe liver or kidney disease is a hard stop.
Any ibogaine provider who skips the pre-ceremony EKG is not operating safely. The cardiac screening is not optional infrastructure — it is what catches the conditions that make ibogaine a fatality risk rather than a therapeutic tool. A low-cost ibogaine ceremony is almost always one where something medically necessary has been removed from the protocol.
For the complete list of ibogaine contraindications, the ibogaine contraindications guide covers the cardiac, medication, and psychiatric conditions in detail. For the legal and regulatory context in Canada, ibogaine therapy in Canada explains what ibogaine's non-schedule status actually means in practice.
Who This Is Not For
This comparison is not useful for someone deciding between two substances on preference. The decision between ibogaine and psilocybin is a clinical question with a condition-specific answer. If neither condition profile fits, neither medicine is indicated at this time.
Transcend works specifically with ibogaine and 5-MeO-DMT in Vancouver, BC. We do not offer psilocybin sessions. If you have treatment-resistant depression without addiction history and no cardiac complications, ibogaine may not be the appropriate first medicine to pursue. The evidence base for psilocybin in that specific profile is more developed. We say this directly because the alternative — telling everyone that ibogaine is right for everyone — is not accurate and not a position we take.
If you have opioid dependence, polysubstance addiction, or PTSD complicated by prior treatment failure, the comparison points clearly toward ibogaine. If you have documented QT prolongation or cardiac conditions that cannot be resolved through screening, ibogaine is not available to you regardless of preference.
For a broader view of how ibogaine compares to other plant medicines, ibogaine vs mushrooms covers the same medicines from a different angle. The ibogaine vs 5-MeO-DMT comparison covers the two medicines Transcend works with and how that choice is made during intake.
Frequently Asked Questions
What is the main difference between ibogaine and psilocybin?
The receptor profiles and primary clinical applications differ substantially. Psilocybin acts primarily through the 5-HT2A serotonin receptor, disrupting the default mode network, with the strongest evidence base for treatment-resistant depression. Ibogaine acts across at least six receptor systems simultaneously — including opioid, NMDA, and serotonin receptors — and is the only psychedelic compound with a mechanism specific to interrupting physical opioid withdrawal. Duration also differs: psilocybin produces a 4–6 hour experience; ibogaine produces a 12–24 hour experience requiring medical monitoring throughout.
Is ibogaine or psilocybin better for depression?
The evidence base tilts toward psilocybin for treatment-resistant depression without addiction. Psilocybin has two published randomised controlled trials in this domain, FDA Breakthrough Therapy designation, and completed Phase 3 trials. Ibogaine's most significant depression findings come from the 2023 Stanford study — 87% reduction in depression symptoms at one month — in a veteran population with co-occurring PTSD and addiction, without a placebo arm. For treatment-resistant depression without substance dependence or cardiac complications, psilocybin has the stronger evidence base. For depression complicated by addiction or treatment-resistant PTSD, ibogaine's multi-system mechanism may be more appropriate.
Can psilocybin treat opioid addiction?
Not through the same mechanism as ibogaine. Psilocybin has no activity at opioid receptors and no mechanism for interrupting physical opioid withdrawal. Early research shows psilocybin may assist with tobacco cessation and alcohol use disorder — conditions where psychological craving rather than physical receptor dependence is the primary barrier. For opioid dependence specifically, ibogaine is the mechanism-appropriate choice. Psilocybin-assisted therapy for opioid dependence would address psychological components but cannot replicate ibogaine's pharmacological interruption of physical withdrawal.
Is psilocybin safer than ibogaine?
Psilocybin carries significantly lower physiological risk. It does not affect the QT interval, does not carry cardiac contraindications, and requires no EKG before administration. Ibogaine prolongs the QT interval — this is the mechanism behind documented fatalities, and requires comprehensive cardiac screening before every ceremony. Psilocybin's primary risks are psychological: it can destabilise psychosis-spectrum conditions, carries seizure risk if combined with lithium, and should not be combined with MAOIs. Both require professional supervision. But the cardiac risk profile of ibogaine has no equivalent in psilocybin.
Can you take ibogaine if you are on SSRIs?
Not without a completed, physician-supervised taper first. SSRIs are an absolute contraindication for ibogaine — the serotonin syndrome risk is real and potentially fatal. The taper timeline depends on the specific medication: fluoxetine requires a longer washout than sertraline or escitalopram. The taper must be completed under physician oversight, not self-managed. This is the most common contraindication we work through during intake. For psilocybin, SSRIs blunt the therapeutic effect rather than creating acute physiological risk.
Which has more clinical research — ibogaine or psilocybin?
Psilocybin has a significantly more developed RCT evidence base. It has FDA Breakthrough Therapy designation for treatment-resistant depression, completed Phase 3 trials, and multiple published randomised controlled trials with control arms. Ibogaine's scheduling as Schedule I in the United States effectively constrained clinical research for 50 years — the evidence that exists was accumulated largely outside the US and through observational rather than controlled study designs. Texas allocated $50 million for ibogaine clinical trials in 2024, and the FDA has authorised investigational new drug applications for noribogaine — ibogaine's primary metabolite — for opioid and alcohol use disorder. The methodological gap is narrowing.
Is ibogaine legal in Canada while psilocybin is not?
Ibogaine is not listed under Canada's Controlled Drugs and Substances Act and is not explicitly prohibited — a meaningfully different position from Schedule I in the US or Class A in the UK. Ibogaine ceremony at Transcend in Vancouver operates legally. Psilocybin remains a controlled substance in Canada, though Health Canada has approved Section 56 exemptions for therapeutic use in specific clinical and end-of-life contexts since 2020. Legal status does not determine which medicine is clinically appropriate for which condition.
Who should consider psilocybin instead of ibogaine?
People with documented QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction are not candidates for ibogaine. People on medications that cannot be safely tapered — certain antipsychotics, lithium, or methadone without the required transition protocol — face ibogaine contraindications that may not apply to psilocybin. If the primary condition is treatment-resistant depression without addiction history and without cardiac complications, psilocybin has a more developed evidence base and a lower medical risk profile. Ibogaine is the clearer choice for opioid dependence, polysubstance addiction, and complex PTSD presentations that have not responded to prior treatment.